Payment overview · 2025
General Payments
$1,175.16
68 reported records · 16 companies
Healthcare provider profile · identity verified
Kris B Cummings, MD
Allopathic & Osteopathic Physicians|Internal Medicine · KINSTON, NC · NPI 1326259425
Verified facts
What the public records show
CMS Open Payments records show Kris B Cummings, MD received $1,175.16 in general payments during 2025 across 68 reported records.
PFIZER INC. accounted for 14.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 30 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Linzess, Synthroid, Trelegy Ellipta, Wegovy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Rybelsus by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Wegovy by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 109 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $172.49 | 14.7% | 10 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $167.62 | 14.3% | 10 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $161.09 | 13.7% | 13 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $125.89 | 10.7% | 5 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $82.66 | 7.0% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $79.15 | 6.7% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $72.41 | 6.2% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $60.71 | 5.2% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $58.91 | 5.0% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $45.93 | 3.9% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $35.26 | 3.0% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $33.87 | 2.9% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $29.02 | 2.5% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $18.16 | 1.6% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.23 | 1.4% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $15.76 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,175.16 | 68 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $172.49 | 10 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $141.65 | 6 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $133.73 | 11 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $133.73 | 11 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $120.47 | 7 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $101.78 | 6 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $93.34 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $79.15 | 6 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $72.41 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $72.41 | 4 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $64.46 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $60.71 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $58.91 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $47.85 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $35.26 | 2 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $33.87 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $31.30 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $31.30 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $30.81 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $29.02 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $27.44 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $27.36 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $19.71 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $18.69 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 2 Normalized: freestyle libre 2 |
Device | Abbott Laboratories | $18.20 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $18.16 | 1 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $18.16 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $16.23 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $15.12 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $13.14 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 109 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 55 | exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 79 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 101 | exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
55 | 12 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
79 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
101 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
95 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
109 | 24 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 521 | 131 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 491 | 128 |
| Atorvastatin Calcium | Atorvastatin Calcium | 470 | 120 |
| Levothyroxine Sodium | Levothyroxine Sodium | 418 | 84 |
| Omeprazole | Omeprazole | 397 | 97 |
| Gabapentin | Gabapentin | 299 | 64 |
| Losartan Potassium | Losartan Potassium | 273 | 72 |
| Simvastatin | Simvastatin | 267 | 73 |
| Lisinopril | Lisinopril | 266 | 74 |
| Hydrochlorothiazide | Hydrochlorothiazide | 230 | 57 |
| Potassium Chloride | Potassium Chloride | 212 | 51 |
| Meloxicam | Meloxicam | 204 | 44 |
| Metformin Hcl | Metformin Hcl | 196 | 56 |
| Metoprolol Succinate | Metoprolol Succinate | 186 | 52 |
| Metoprolol Tartrate | Metoprolol Tartrate | 172 | 35 |
| Furosemide | Furosemide | 167 | 45 |
| Trazodone Hcl | Trazodone Hcl | 155 | 38 |
| Zolpidem Tartrate | Zolpidem Tartrate | 150 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 140 | 56 |
| Tramadol Hcl | Tramadol Hcl | 140 | 33 |
| Tamsulosin Hcl | Tamsulosin Hcl | 135 | 34 |
| Allopurinol | Allopurinol | 126 | 29 |
| Duloxetine Hcl | Duloxetine Hcl | 123 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 123 | 24 |
| Famotidine | Famotidine | 120 | 31 |
| Pantoprazole Sodium | Pantoprazole Sodium | 117 | 38 |
| Sertraline Hcl | Sertraline Hcl | 115 | 32 |
| Eliquis | Apixaban | 109 | 24 |
| Atenolol | Atenolol | 104 | 22 |
| Carvedilol | Carvedilol | 104 | 31 |
| Spironolactone | Spironolactone | 102 | 26 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 101 | 23 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 101 | 13 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 100 | 29 |
| Fluoxetine Hcl | Fluoxetine Hcl | 97 | 18 |
| Metformin Hcl Er | Metformin Hcl | 96 | 29 |
| Ozempic | Semaglutide | 95 | 13 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 90 | 16 |
| Montelukast Sodium | Montelukast Sodium | 88 | 23 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 81 | 31 |
| Myrbetriq | Mirabegron | 81 | 16 |
| Paroxetine Hcl | Paroxetine Hcl | 79 | 17 |
| Synthroid | Levothyroxine Sodium | 79 | 14 |
| Alprazolam | Alprazolam | 78 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 77 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 69 | 17 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 66 | 12 |
| Clonazepam | Clonazepam | 65 | 12 |
| Lorazepam | Lorazepam | 64 | suppressed |
| Prednisone | Prednisone | 64 | 51 |
| Buspirone Hcl | Buspirone Hcl | 62 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 61 | 12 |
| Bupropion Xl | Bupropion Hcl | 60 | 11 |
| Ezetimibe | Ezetimibe | 57 | 11 |
| Linzess | Linaclotide | 55 | 12 |
| Pregabalin | Pregabalin | 53 | 12 |
| Irbesartan | Irbesartan | 52 | 13 |
| Glipizide Er | Glipizide | 51 | 11 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 48 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 48 | 12 |
| Temazepam | Temazepam | 48 | suppressed |
| Verapamil Er | Verapamil Hcl | 48 | suppressed |
| Finasteride | Finasteride | 47 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 46 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 45 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 45 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 45 | suppressed |
| Lansoprazole | Lansoprazole | 44 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 44 | 13 |
| Valacyclovir | Valacyclovir Hcl | 44 | 15 |
| Colchicine | Colchicine | 40 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 40 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 40 | 35 |
| Azithromycin | Azithromycin | 39 | 37 |
| Benazepril Hcl | Benazepril Hcl | 39 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 39 | 16 |
| Ibuprofen | Ibuprofen | 37 | suppressed |
| Baclofen | Baclofen | 36 | suppressed |
| Trulicity | Dulaglutide | 34 | suppressed |
| Butalbital-Aspirin-Caffeine | Butalbital/Aspirin/Caffeine | 33 | suppressed |
| Jardiance | Empagliflozin | 33 | suppressed |
| Valsartan | Valsartan | 33 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 32 | suppressed |
| Repatha Sureclick | Evolocumab | 32 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 31 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 31 | suppressed |
| Fenofibrate | Fenofibrate | 31 | suppressed |
| Nystatin | Nystatin | 31 | 21 |
| Entresto | Sacubitril/Valsartan | 30 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 30 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 29 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 29 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 29 | 19 |
| Warfarin Sodium | Warfarin Sodium | 29 | suppressed |
| Digoxin | Digoxin | 28 | suppressed |
| Torsemide | Torsemide | 28 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 28 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 28 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 26 | 22 |
| Diazepam | Diazepam | 26 | suppressed |
| Mirtazapine | Mirtazapine | 26 | suppressed |
| Naproxen | Naproxen | 26 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 26 | suppressed |
| Carisoprodol | Carisoprodol | 25 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 25 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 25 | suppressed |
| Rybelsus | Semaglutide | 25 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 24 | 23 |
| Celecoxib | Celecoxib | 24 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 24 | suppressed |
| Fluconazole | Fluconazole | 24 | 19 |
| Pioglitazone Hcl | Pioglitazone Hcl | 24 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 23 | suppressed |
| Chlorthalidone | Chlorthalidone | 23 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 22 | suppressed |
| Klor-Con M20 | Potassium Chloride | 22 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 22 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | 11 |
| Donepezil Hcl | Donepezil Hcl | 21 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 20 | 16 |
| Glipizide | Glipizide | 20 | suppressed |
| Primidone | Primidone | 20 | suppressed |
| Tradjenta | Linagliptin | 20 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 20 | suppressed |
| Eszopiclone | Eszopiclone | 19 | suppressed |
| Ondansetron Odt | Ondansetron | 19 | suppressed |
| Bumetanide | Bumetanide | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 18 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 17 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 17 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 17 | suppressed |
| Estradiol | Estradiol | 17 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 17 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 16 | suppressed |
| Hydrocortisone | Hydrocortisone | 16 | 14 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 16 | suppressed |
| Januvia | Sitagliptin Phosphate | 16 | suppressed |
| Ranolazine Er | Ranolazine | 16 | suppressed |
| Belsomra | Suvorexant | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 15 | suppressed |
| Wegovy | Semaglutide | 15 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 14 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 14 | 11 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 14 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Probenecid | Probenecid | 13 | suppressed |
| Testosterone | Testosterone | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Zafirlukast | Zafirlukast | 13 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 12 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 12 | suppressed |
| Indapamide | Indapamide | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Trulance | Plecanatide | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 11 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 11 | suppressed |
| Carbamazepine Er | Carbamazepine | 11 | suppressed |
| Easy Touch Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 11 | suppressed |
| Victoza 2-Pak | Liraglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,175.16 · 68 records | PFIZER INC. | AIRSUPRA, AREXVY, BREZTRI, Cologuard Collection Kit, ELIQUIS, EVENITY, FANAPT, FREESTYLE LIBRE 2, FREESTYLE LIBRE 3, GEMTESA, GVOKE HYPOPEN, HETLIOZ, LEQVIO, LINZESS, Leqembi, MOUNJARO, NURTEC ODT, OTEZLA, PROLIA, QULIPTA, REPATHA, REXULTI, SHINGRIX, SYNTHROID, TRELEGY ELLIPTA, UBRELVY, VRAYLAR, Wegovy, ZAVZPRET, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error